Medicus Pharma has submitted a Phase 2b clinical trial protocol to the FDA for SkinJect®, targeting Gorlin Syndrome, a rare genetic disorder causing multiple skin cancers. This trial aims to support a future New Drug Application for what could be the first FDA-approved lesion-directed therapy for this condition, which currently lacks effective treatments. The study will evaluate visual clearance of skin lesions, potentially reducing the need for repeated surgeries in patients. Medicus also seeks orphan drug designation and a Rare Pediatric Disease Priority Review Voucher to expedite development and market entry.
The global automotive microcontrollers market is projected to grow from USD 15.49 billion in 2025 to USD 34.31 billion by 2035, at a CAGR of 8.28%. Growth is fueled by increasing adoption of advanced driver-assistance systems (ADAS), vehicle electrif...
B&M European Value Retail's first-quarter update has divided analysts, with Deutsche Bank upgrading the stock to 'hold' citing stabilizing profit margins and a sensible turnaround strategy by new CEO Tjeerd Jegen. Deutsche Bank raised its profit fore...
Meta now notifies parents if their teen talks about suicide or self-harm with its AI chatbot and is developing a feature to contact emergency services if risk is detected. This move addresses concerns about AI chatbots handling crisis conversations, ...
Garmin introduced the G2000 PRIME, a new integrated flight deck designed for high-performance Class I/II piston and electric aircraft. It features large, edge-to-edge touchscreen displays with advanced multi-touch capabilities, faster processors, and...
UniFirst Corporation has been recognized on Selling Power's 60 Best Companies to Sell For list for the 23rd consecutive year, highlighting its strong sales culture and support for sales professionals. The list evaluates companies on compensation, tra...
